PROJECT

Projects

Environmental & Social Review Summary

Project Number

47539

Company Name

PT. TAWADA HEALTHCARE

Date ESRS Disclosed

Jun 30, 2023

Country

Indonesia

Region

East Asia and the Pacific

Last Updated Date

Sep 29, 2023

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Sep 11, 2023
Signed : Sep 14, 2023
Invested : Sep 22, 2023

Sector

other

Industry

other

Department

Regional Industry - MAS Asia & Pac

Project Description

 PT Tawada Healthcare (“Tawada” or “the Company”, https://www.tawadahealthcare.com/), established in 1999, is one of the largest medical device distribution company in Indonesia. Tawada has 15 branch offices and operates in over 24 cities across different islands in Indonesia. Tawada has a central warehouse (about 3000 sqm, two stories) located in Cikupa, Tangerang Regency, and the headquarter and each branch office have small warehousing storage capacity. The company owns some motorcycles and vans for delivery services within the city area.

 

Tawada’s principal business is distribution of medical devices and healthcare consumables including: (i) healthcare consumables distribution (i.e. films, syringes, stents, dialysis solution) and (ii) capital equipment distribution (i.e. diagnostics, gastro & surgery equipment, microsurgery machines, amongst others).

 

Tawada has following group companies: AIC Medical Clinic, PT THC Martin Indonesia, THC Martin Industri, THC Medika Industri, and Triputra Aman Makmur and two of them are manufacturing entities.

- THC Martin Industri, finishing surgical instruments locally such as forceps, retractors, bowl and tray.

- THC Medika Industri, providing water treatment solution to hospitals by assembling reverse oasis filtration system and producing hemodialysis solution.

IFC proposes an equity investment in Tawada of up to US$15 million equivalent in Indonesian Rupiah (IDR).  IFC investment will be used to support the company’s capital expenditure for development of its manufacturing facility, acquisitions, and working capital including: (i) the acquisitions of one or several companies with medical device distribution and/or manufacturing capabilities that will leverage the Company’s existing platform; (ii) capital expenditure to build its manufacturing capabilities (about 2 ha) in an industrial park, in Batang Central Java Province; and (iii) to fund the company’s working capital needs.

Overview of IFC's Scope of Review

 IFC’s review of the proposed investment was conducted in April 2023, included review of environmental, health and safety (EHS) and social information provided by Tawada, covering corporate EHS procedures, Human Resource (HR) policies and manuals, emergency response procedures, and interviews with the senior management of Tawada including persons in charge of acquisition and new factory development, human resource management and the managers in charge of warehouse and factory operations. The Environment and Social (E&S) review included site visits to the existing factories and the central warehouse in Cikupa in April 2023.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan